Lance Berman is a Venture Partner at Ysios Capital who spent over 20 years working as a physician and executive in biotech and pharma, including as Chief Medical Officer at Pulmocide and AELIX and Senior Vice President at Relypsa, before moving into investing. His clinical background in areas like anti-infectives, pulmonary medicine, and HIV vaccine research, combined with experience across Africa, Europe, and the US, gives him a hands-on, science-first perspective that's grounded in company-building rather than pure finance.
About their Fund
Ysios Capital is Spain's largest life sciences venture capital firm, with ties to Spain's science leadership through cofounder Cristina Garmendia, who left the firm to serve as Spain's Minister of Science and Innovation before returning as a partner, and it has moved beyond typical venture investing into company creation through its InceptionBio vehicle, which builds biotech companies from early tech-transfer projects with a strong focus on Spain. The firm focuses on hard science areas like gene therapy, oncology, orphan CNS disease, calcification disorders, and regenerative cardiovascular implants, has backed deals such as Sanifit's acquisition by Vifor Pharma and U.S.-based Kala Pharmaceuticals, and produced three NASDAQ IPOs in 2021 alongside its oversubscribed €216M third fund.
















.jpeg)







.jpeg)











































































.png)
























































































































.jpeg)









.jpeg)




















































































